Every 424B that 20/20 Biolabs Inc (AIDX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AIDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIDX filings page.
20/20 Biolabs, Inc. is updating its resale registration covering up to 15,164,724 shares of common stock held by certain selling stockholders, incorporating its quarterly results for the period ended June 30, 2026.
For the quarter, revenue rose to $730,571 from $535,060, driven mainly by higher OneTest cancer-screening sales, especially to Maryland firefighter programs. Gross margin improved to 41.71% from 30.51%. However, higher public-company, stock-based compensation and investor-relations costs pushed operating expenses to $1.55 million, widening the quarterly net loss to $1.51 million versus $0.84 million a year earlier.
For the first six months, revenue was essentially flat at $1.08 million, while the net loss increased to $3.68 million from $1.61 million, reflecting increased operating and financing costs, including losses tied to convertible notes and warrant-related derivatives. As of June 30, 2026, the company held $4.55 million in cash and cash equivalents and $2.52 million in working capital, supported by a $6.0 million Series E preferred stock financing and related convertible debt transactions. Management notes recent losses may continue and that failure to secure adequate capital could eventually force a cessation of operations.
20/20 Biolabs, Inc. is updating a resale registration statement covering up to 10,105,000 shares of common stock held by selling stockholders, while incorporating its quarterly results for the period ended June 30, 2026. The common stock trades on Nasdaq under “AIDX,” closing at $0.549 on August 14, 2026, with 12,770,303 shares outstanding.
For the second quarter, revenue rose to $730,571, up 36.54% year over year, driven mainly by 47.08% growth in OneTest sales, while quarterly gross margin improved to 41.71%. However, higher public-company and growth-related costs pushed the quarterly net loss to $1,506,343; the six‑month net loss reached $3,681,180.
Liquidity improved through a $6,000,000 private placement of Series E convertible preferred stock, lifting cash to $4,546,140 and working capital to $2,524,386. As of June 30, 2026, 5,228 Series E preferred shares were outstanding, senior to common stock and convertible into common shares, alongside 3,656,172 outstanding warrants, creating potential future dilution.
20/20 Biolabs, Inc. files a prospectus supplement to include its Form 10-Q and updates a resale registration for 10,105,000 shares of common stock for certain selling stockholders. The company reported cash and cash equivalents of $4,219,099, net loss of $2,174,836 for the three months ended March 31, 2026, and disclosed 5,000 shares of Series E convertible preferred stock outstanding.
The supplement references the company’s Nasdaq listing under the symbol AIDX and includes operating results showing decreased revenues to $353,375 for the quarter and working capital of $2,120,232. Management disclosed material weaknesses in internal controls and described remedial steps underway.
20/20 Biolabs, Inc. files a prospectus supplement registering 15,164,724 shares of common stock for resale by selling stockholders.
The filing incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026, shows cash of $4,219,099 and a net loss of $2,174,836 for the three months then ended. Shares outstanding were 10,611,528 as of May 19, 2026.
20/20 Biolabs, Inc. registered 15,164,724 shares of common stock for resale by certain selling stockholders. This Prospectus Supplement No. 1 amends the April 9, 2026 prospectus to include the Current Report on Form 8-K filed April 28, 2026.
The Form 8-K discloses a Global Amendment dated April 23, 2026 with Streeterville Capital that reduces the exercise price of three previously issued warrants to $2.25 per share ("subject to standard adjustments for stock splits, stock dividends, recapitalizations and similar transactions"). The Amendment permits the Company to terminate the Amendment within ninety (90) days after execution upon at least two (2) trading days' written notice, during which period Streeterville may exercise the warrants at the reduced price. The filing also notes a Nasdaq listing price used in prior transactions of $11.42 and a closing Nasdaq price on April 24, 2026 of $1.64.
20/20 Biolabs filed a Prospectus Supplement to register the resale of 10,105,000 shares of common stock by certain selling stockholders. The Supplement incorporates an April 28, 2026 Form 8-K that discloses a Global Amendment with Streeterville Capital reducing the warrants' exercise price to $2.25. The cover notes the company's Nasdaq symbol AIDX and a closing share price of $1.64 on April 24, 2026.
The 8-K summarizes prior private placements with Streeterville, including secured convertible promissory notes and multiple warrants (Warrant 1, Warrant 2, Warrant 3), a February 19, 2026 issuance of series E convertible preferred stock, and the Amendment that changes warrant economics and requires a sticker update to the registration statement. The Supplement is qualified by and should be read together with the Prospectus dated April 10, 2026.
20/20 Biolabs, Inc. registered 10,105,000 shares of common stock for resale by a selling stockholder; these shares may be sold from time to time. The prospectus dated April 10, 2026 states the company will not receive proceeds from those resales or from conversion of series E preferred or the secured convertible note, but will receive funds if the selling stockholder exercises a warrant. The prospectus lists components of the 10,105,000 shares including 475,000 previously issued shares, 62,500 issuable on warrant exercise, up to 42,500 issuable on conversion of a secured convertible note, and up to 9,525,000 issuable on conversion of series E preferred stock. As of the prospectus date there were 10,480,089 shares issued and outstanding. The company’s common stock trades on Nasdaq under the symbol AIDX and the prospectus cites a last reported sale price of $1.84 on April 9, 2026.
20/20 Biolabs, Inc. registers 15,164,724 shares of common stock for resale by selling stockholders in connection with its Nasdaq direct listing. The prospectus states the resale is not underwritten and that the company will receive no proceeds from sales by the selling stockholders. As of the date of the prospectus, 10,480,089 shares were issued and outstanding.
The prospectus discloses the company’s product focus on AI-powered blood tests (OneTest for Cancer and OneTest for Longevity), recent financial results including 2025 revenues of $2,045,133 and a net loss of $3,738,821, and risk factors related to commercialization, regulatory change, and liquidity.